在2025年世界艾滋病日,非洲发起了lenacapavir,这是每年两次非常有效的艾滋病毒预防注射,一年两次,在资金短缺威胁到获得治疗的机会的情况下。 On World AIDS Day 2025, Africa launched lenacapavir, a highly effective twice-yearly HIV prevention injection, amid funding shortfalls threatening access.

在2025年世界艾滋病日,南非、埃斯瓦蒂尼和赞比亚开始推出莱纳卡帕维尔(lenacapavir),这是每年两次注射的艾滋病毒预防药物,有效率超过99.9%,是非洲首次公开使用。 On World AIDS Day 2025, South Africa, Eswatini, and Zambia began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug with over 99.9% effectiveness, marking the first public use in Africa. 长效暴露前预防 (PrEP) 已于2025年10月被世卫组织批准,为每日服用药物提供了关键的替代方案,改善了药物遵守率并减少了耻辱感. Approved by WHO in October 2025, the long-acting pre-exposure prophylaxis (PrEP) offers a critical alternative to daily pills, improving adherence and reducing stigma. Gilead Science公司正在三年内向中低收入国家200万人提供这种药物,但无利可图,预计到2027年将使用通用药物。 Gilead Sciences is providing the drug at no profit to two million people in low- and middle-income countries over three years, with generic versions expected by 2027. 尽管取得了这一进展,但国际资金削减干扰了艾滋病毒防治服务,估计有250万人无法获得普雷夫普雷夫治疗。 Despite this progress, international funding cuts have disrupted HIV services, leaving an estimated 2.5 million people without PrEP access. 世卫组织警告说,持续投资和公平准入是实现2030年消灭艾滋病目标的关键。 WHO warns that sustained investment and equitable access are essential to achieving the 2030 goal of ending AIDS.